Workflow
Haitong Securities(600837)
icon
Search documents
悍高集团: 国泰海通证券股份有限公司关于悍高集团股份有限公司使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:47
Summary of Key Points Core Viewpoint - The report from Guotai Junan Securities on Hanguo Group's use of raised funds to replace pre-invested self-raised funds and paid issuance expenses indicates compliance with relevant regulations and confirms the appropriateness of the fund usage [1][7]. Group 1: Fundraising Overview - Hanguo Group's initial public offering (IPO) was approved by the China Securities Regulatory Commission, with a total fundraising amount of RMB 617.35 million, and a net amount of RMB 510.62 million after deducting issuance expenses of RMB 106.73 million [1][2]. - As of July 25, 2025, all raised funds have been received, and the funds are managed in a special account as per regulatory requirements [1][2]. Group 2: Investment Project Details - The total investment for the projects outlined in the prospectus is RMB 643.47 million, with RMB 420 million planned to be funded from the raised capital [2][5]. - As of August 1, 2025, Hanguo Group has used RMB 428.19 million of self-raised funds to pre-invest in projects and cover issuance expenses, with RMB 412.61 million allocated to project investments and RMB 15.58 million for issuance expenses [2][5]. Group 3: Replacement of Self-raised Funds - The company plans to use the raised funds to replace RMB 412.61 million of pre-invested self-raised funds and RMB 15.58 million of paid issuance expenses [5][6]. - The replacement of funds is in line with the company's operational needs and will not affect the normal progress of the investment projects [5][7]. Group 4: Compliance and Approval Process - The board of directors and the supervisory board have approved the use of raised funds for replacing pre-invested self-raised funds, confirming adherence to regulatory requirements [6][7]. - Huaxing Accounting Firm has issued a verification report affirming that the company's actions comply with relevant regulations and accurately reflect the use of self-raised funds [7][8].
悍高集团: 国泰海通证券股份有限公司关于悍高集团股份有限公司使用自有资金支付募投项目部分款项并以募集资金等额置换的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:47
Core Viewpoint - The company plans to use its own funds to pay for part of the fundraising project expenses and subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining project efficiency [1][6]. Fundraising Overview - The total amount raised by the company through its initial public offering (IPO) is RMB 617.35 million, with a net amount of RMB 507.62 million after deducting issuance costs [1]. - The company has completed the fundraising process as of July 25, 2025, and has established special accounts for managing the raised funds [1]. Project Investment Details - The total investment for the fundraising projects is RMB 643.47 million, with adjustments leading to a revised investment of RMB 510.62 million [1]. - The projects include the establishment of an automated manufacturing base and a research and development center [1]. Reasons for Using Own Funds - The company faces challenges in directly using raised funds for payroll and other expenses due to regulatory requirements [2]. - The need for centralized procurement and payment efficiency also necessitates the use of own funds initially [2]. - The company aims to enhance operational efficiency and reduce financial costs by using various payment methods [2]. Replacement Process - The company will establish a detailed accounting ledger for the funds used and will regularly transfer equivalent amounts from the fundraising account to its own funds account [3]. - Continuous supervision by the sponsor institution will ensure compliance with the replacement process [3]. Impact on the Company - The use of own funds for project expenses will not affect the normal implementation of the fundraising projects and will not change the intended use of the raised funds [5][6]. - The decision has been approved by both the board of directors and the supervisory board, ensuring adherence to necessary procedures [4][5].
悍高集团: 国泰海通证券股份有限公司关于悍高集团股份有限公司募投项目延期及使用超募资金用于在建募投项目的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:47
Summary of Key Points Core Viewpoint - The company is postponing its fundraising project deadlines and reallocating excess funds to ongoing projects to enhance operational efficiency and ensure the effective use of raised capital [1][3][8]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was approximately RMB 617.35 million, with a net amount of RMB 550.62 million after deducting issuance costs [1][2]. - The company has established special accounts for managing the raised funds, ensuring compliance with regulatory requirements [1][2]. Project Delay Details - The company has decided to adjust the expected completion dates for all fundraising projects to December 2026, while maintaining the original project scope and funding allocation [3][4]. - The delay is attributed to longer installation and debugging periods for automated production lines, as well as fluctuations in market demand [3][4]. Impact of Delay - The postponement is a strategic decision that will not adversely affect the implementation of the projects or the company's normal operations, and is expected to enhance the effective use of funds [3][4][8]. - The company aims to ensure high-quality project execution and long-term healthy development through this delay [3][4]. Use of Excess Funds - The company plans to allocate approximately RMB 90.62 million of excess funds (including interest) to the "Hankao Smart Home Hardware Automation Manufacturing Base Project" [4][5]. - This project aims to improve production capacity and efficiency by introducing advanced equipment and information systems [4][5][6]. Project Investment and Returns - The total investment for the automation manufacturing base project is estimated at RMB 561.17 million, with an expected internal rate of return of 20.07% and a payback period of approximately 6.94 years [6][7]. - The project will significantly enhance the company's production capabilities and meet growing market demands [6][7]. Governance and Approval - The board of directors and the supervisory board have approved the project delays and the use of excess funds, confirming that these actions align with regulatory requirements and the company's interests [7][8]. - The sponsor institution, Guotai Junan Securities, has also expressed no objections to the proposed changes [8].
上海银行: 国泰海通证券股份有限公司关于上海银行股份有限公司关联交易事项的专项核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:25
国泰海通证券股份有限公司 关于上海银行股份有限公司关联交易事项的专项核查意见 国泰海通证券股份有限公司(以下简称"保荐机构")作为上海银行股份有 限公司(以下简称"公司")持续督导的保荐机构,根据《证券发行上市保荐业 务管理办法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律 监管指引第11号——持续督导》等法律、法规及规范性文件的要求,对公司关联 交易事项进行了认真、审慎的核查,核查情况如下: 一、关联交易概述 (一)与上银国际(深圳)的关联交易 经公司董事会2025年第八次会议审议通过,同意调整向上银国际(深圳)有 限公司(以下简称"上银国际(深圳)")转让相关资管计划所持有的资产的支 付进度,其他业务要素保持不变。 上银国际(深圳)属于公司关联方,本次交易构成关联交易。 (二)与新微集团的关联交易 经公司董事会2025年第八次会议审议通过,同意给予上海新微科技集团有限 公司(以下简称"新微集团")人民币4亿元授信额度,用于债务融资工具承销、 持券及投资,授信有效期3年,担保方式为信用。 新微集团属于公司关联方,本次交易构成关联交易。 上述关联交易均不构成《上市公司重大资产重组管理办法》规定的 ...
杰创智能: 国泰海通证券股份有限公司关于杰创智能科技股份有限公司和子公司增加2025年度向银行等金融机构申请综合授信的额度并接受关联方提供担保的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:25
增加 2025 年度向银行等金融机构申请综合授信的额度 并接受关联方提供担保的核查意见 国泰海通证券股份有限公司(以下简称"国泰海通证券"或"保荐机构")作为 杰创智能科技股份有限公司(以下简称"杰创智能"或"公司")首次公开发行股票 并在创业板上市的保荐机构,根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》 国泰海通证券股份有限公司 关于杰创智能科技股份有限公司和子公司 授权公司和子公司的法定代表人代表公司或子公司与银行或非银行金融机 构签署上述授信融资项下的有关法律文件,由此产生的法律、经济责任由公司和 子公司承担。 二、关联方提供担保的情况 (一)关联担保的基本情况 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律法规和 规范性文件的要求,对公司和子公司增加 2025 年度向银行等金融机构申请综合 授信的额度并接受关联方提供担保的事项进行了核查,核查情况如下: 一、增加申请综合授信额度概述 (一)已审批授信额度情况 公司于 2025 年 4 月 18 日召开第四届董事会第十次会议和第四届监事会第七 次会议,于 ...
凯众股份: 国泰海通证券股份有限公司关于上海凯众材料科技股份有限公司向不特定对象发行可转换公司债券第一次临时受托管理事务报告(2025年度)
Zheng Quan Zhi Xing· 2025-08-29 17:25
Group 1 - The company, Shanghai Kaizhong Materials Technology Co., Ltd., is issuing convertible bonds to unspecified investors, with a total face value of RMB 100.00 per bond and a maturity period of six years from August 15, 2025, to August 14, 2031 [2][3][4] - The coupon rates for the bonds are set at 0.20% for the first year, 0.40% for the second year, 0.60% for the third year, and 1.00% for the fourth year, with annual interest payments [3][4][5] - The initial conversion price for the bonds is set at RMB 12.70 per share, which will be adjusted based on specific corporate actions such as stock dividends or capital increases [5][6][7] Group 2 - The bondholders have the right to convert their bonds into shares starting from February 23, 2026, until the maturity date [4][5] - The company has provisions for redeeming the bonds at 110% of the face value plus the last year's interest within five trading days after maturity, and can also redeem the bonds under certain conditions during the conversion period [9][10] - The company will not provide any guarantees for the bonds, and the credit rating for the bonds is AA- with a stable outlook [14][15] Group 3 - The company has made changes to its corporate governance structure by abolishing the supervisory board, with the responsibilities being transferred to the audit committee of the board of directors [16][17] - These changes are in compliance with the new Company Law and are not expected to adversely affect the safety of the bondholders' principal and interest or the company's debt repayment capacity [16][17]
之江生物: 国泰海通证券股份有限公司关于上海之江生物科技股份有限公司增加使用部分暂时闲置募集资金进行现金管理的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:03
Core Viewpoint - The company intends to increase the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and maximize shareholder returns while ensuring the safety of the raised funds and the implementation of investment projects [1][5][7]. Summary by Sections Fundraising Basic Situation - The company was approved for its initial public offering (IPO) on November 27, 2020, with a total of 48.676088 million shares issued at a price of RMB 43.22 per share, raising a total of RMB 2,103.7805 million. After deducting issuance costs, the net amount raised was RMB 1,942.3216 million [1]. Fund Investment Project Basic Situation - The total planned investment for the projects funded by the raised capital is RMB 1,355.8911 million, with the same amount allocated for fundraising [2]. Previous Use of Idle Funds for Cash Management - The company previously approved the use of up to RMB 880 million of temporarily idle funds for cash management, allowing for the purchase of safe, liquid financial products. This approval is valid for 12 months from the board's decision [2][3]. Current Increase in Cash Management Usage - The company plans to increase the cash management limit by RMB 60 million, bringing the total to RMB 940 million. This increase is also valid for 12 months from the board's approval [4][6]. Investment Purpose - The aim is to rationally utilize temporarily idle funds for cash management to improve fund efficiency and increase returns for shareholders, without affecting the implementation of investment projects [3][5]. Investment Products - The company will invest in high-safety, principal-protected, and liquid products, including but not limited to guaranteed financial products, structured deposits, large certificates of deposit, and time deposits [4]. Implementation and Disclosure - The company’s chairman is authorized to make investment decisions within the approved limits, and the finance department will organize the implementation. The company will comply with relevant disclosure obligations [4][5]. Impact on the Company - The increase in cash management usage will not affect the normal operation of the company’s funds or the implementation of investment projects, and it is expected to generate additional investment returns for the company and its shareholders [5][7]. Review Procedures and Opinions - The board and supervisory committee have approved the increase in cash management usage, confirming that it aligns with legal requirements and does not harm the interests of the company or minority shareholders [6][7].
之江生物: 国泰海通证券股份有限公司关于上海之江生物科技股份有限公司部分募投项目变更的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:03
《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》 《上 国泰海通证券股份有限公司 关于上海之江生物科技股份有限公司 部分募投项目变更的核查意见 国泰海通证券股份有限公司(以下简称"国泰海通"或"保荐人")作为上 海之江生物科技股份有限公司(以下简称"之江生物"、"公司"或"发行人") 首次公开发行股票并在科创板上市的保荐人,根据《证券发行上市保荐业务管理 办法》 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律法 规和规范性文件的要求,对之江生物部分募投项目变更的事项进行了核查,核查 情况如下: 一、变更募集资金投资项目的概述 (一)募集资金基本情况 公司首次公开发行股票并在科创板上市的注册申请于 2020 年 11 月 27 日经 中国证券监督管理委员会同意注册(证监许可[2020]3214 号《关于同意上海之江 生物科技股份有限公司首次公开发行股票注册的批复》)。公司获准向社会公开发 行人民币普通股(A 股)股票 4,867.6088 万股,每股发行价格人民币 43.22 元, 募集资金合计 210,378.05 万元,扣除发行费用后,实际募集资金净额为 194, ...
金海通: 国泰海通证券股份有限公司关于天津金海通半导体设备股份有限公司调整部分募投项目内部投资结构的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:03
国泰海通证券股份有限公司 关于天津金海通半导体设备股份有限公司 调整部分募投项目内部投资结构的核查意见 | 序 | | | 募集资金累计 | | 单位:万元 | | | --- | --- | --- | --- | --- | --- | --- | | | 项目名称 | 拟投资总额 | | | 投入进度 | 变动情况 | | 号 | | | 投入金额 | | | | | | 半导体测试设备智能制 | | | | 拟调整内部 | | | | | | | | 投资结构 | | | | 项目 | | | | | | | 序 | | | 募集资金累计 | | | | | | 项目名称 | 拟投资总额 | | | 投入进度 | 变动情况 | | 号 | | | 投入金额 | | | | | | 年产1,000台(套)半导 | | (注1) | (注2) | 3) | | | | 件及组件项目 | | | | | | | | | | | (注4) | | | 合计 74,681.19 49,533.42 注 1:"年产 1,000 台(套)半导体测试分选机机械零配件及组件项目"募集资金累计投入 金额中包含暂未支付的合 ...
华虹公司: 国泰海通证券股份有限公司关于华虹半导体有限公司聘任高级管理人员及核心技术人员调整的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:03
国泰海通证券股份有限公司 关于华虹半导体有限公司 聘任高级管理人员及核心技术人员调整的核查意见 国泰海通证券股份有限公司(以下简称"保荐机构")作为华虹半导体有限公 司(以下简称"华虹公司"或"公司")首次公开发行人民币普通股(A股)股票并 在科创板上市的保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第11号——持 续督导》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有 关规定,对华虹公司高级管理人员暨核心技术人员调整的事项进行了审慎核查,具 体情况如下: 一、委任高级管理人员及核心技术人员的情况 经公司董事会于2025年8月28日作出决议,同意委任陈一敏女士担任公司的执行 副总裁;同时,公司认定陈广龙先生为公司的核心技术人员。陈一敏女士与陈广龙 先生的简历如下: 陈一敏女士,43岁,现任公司、上海华虹宏力半导体制造有限公司(以下简称 "上海华虹宏力")、华虹半导体(无锡)有限公司(以下简称"华虹无锡")及 华虹半导体制造(无锡)有限公司(以下简称"华虹制造")执行副总裁、上海华 虹宏力党委副书记,协管人力资源工作。 ...